KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Total Liabilities (2016 - 2026)

Esperion Therapeutics filings provide 9 years of Total Liabilities readings, the most recent being $767.9 million for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 4.82% to $767.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $767.9 million, a 4.82% increase, with the full-year FY2025 number at $767.9 million, up 4.82% from a year prior.
  • Total Liabilities hit $767.9 million in Q4 2025 for Esperion Therapeutics, down from $815.4 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $815.4 million in Q3 2025 to a low of $548.0 million in Q1 2021.
  • Median Total Liabilities over the past 5 years was $619.1 million (2022), compared with a mean of $652.0 million.
  • Biggest five-year swings in Total Liabilities: skyrocketed 142.95% in 2021 and later fell 1.76% in 2023.
  • Esperion Therapeutics' Total Liabilities stood at $578.5 million in 2021, then decreased by 1.18% to $571.7 million in 2022, then rose by 15.58% to $660.8 million in 2023, then rose by 10.86% to $732.5 million in 2024, then rose by 4.82% to $767.9 million in 2025.
  • The last three reported values for Total Liabilities were $767.9 million (Q4 2025), $815.4 million (Q3 2025), and $780.6 million (Q2 2025) per Business Quant data.